These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 31070616)

  • 1. Enzyme-mediated dual-targeted-assembly realizes a synergistic anticancer effect.
    Mang D; Zhang S; Wu X; Hu X; Mochizuki T; Li G; Zhang Y
    Chem Commun (Camb); 2019 May; 55(43):6126-6129. PubMed ID: 31070616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An enzyme-instructed self-assembly system induces tumor acidosis via sequential-dual effect for cancer selective therapy.
    Zhang H; Wang Z; Gao T; Wang Z; Ren C; Liu J
    Acta Biomater; 2023 Jul; 164():447-457. PubMed ID: 36996995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
    Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties.
    Yin T; Liu J; Zhao Z; Dong L; Cai H; Yin L; Zhou J; Huo M
    J Control Release; 2016 Dec; 243():54-68. PubMed ID: 27702595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
    Yan J; Wang Y; Jia Y; Liu S; Tian C; Pan W; Liu X; Wang H
    Biomed Pharmacother; 2017 Apr; 88():374-383. PubMed ID: 28122302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1.
    Hu C; Chen X; Huang Y; Chen Y
    Apoptosis; 2018 Feb; 23(2):132-142. PubMed ID: 29397453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
    Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Peptide-Doxorubicin Co-Assembly for Synergistic Cancer Therapy.
    Li S; Chen X; Chen H; Peng J; Yang X
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: Enzyme-mediated dual-targeted-assembly realizes a synergistic anticancer effect.
    Mang D; Zhang S; Wu X; Hu X; Mochizuki T; Li G; Zhang Y
    Chem Commun (Camb); 2019 Jul; 55(52):7566-7567. PubMed ID: 31190033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine.
    Jiang QW; Cheng KJ; Mei XL; Qiu JG; Zhang WJ; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Zhang X; Lv M; Chen MW; Wei X; Shi Z
    Oncotarget; 2015 Oct; 6(32):32790-804. PubMed ID: 26447544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of concern: Enzyme-mediated dual-targeted-assembly realizes a synergistic anticancer effect.
    Kelly R
    Chem Commun (Camb); 2021 Jul; 57(54):6692. PubMed ID: 34165115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Core-matched nanoassemblies for targeted co-delivery of chemotherapy and photosensitizer to treat drug-resistant cancer.
    Jiang D; Xu M; Pei Y; Huang Y; Chen Y; Ma F; Lu H; Chen J
    Acta Biomater; 2019 Apr; 88():406-421. PubMed ID: 30763634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
    Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
    Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Anticancer Effect of Peptide-Docetaxel Nanoassembly Targeted to Tubulin: Toward Development of Dual Warhead Containing Nanomedicine.
    Mohapatra S; Saha A; Mondal P; Jana B; Ghosh S; Biswas A; Ghosh S
    Adv Healthc Mater; 2017 Jan; 6(2):. PubMed ID: 27782376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
    Sen K; Banerjee S; Mandal M
    Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypericin-functionalized graphene oxide for enhanced mitochondria-targeting and synergistic anticancer effect.
    Han C; Zhang C; Ma T; Zhang C; Luo J; Xu X; Zhao H; Chen Y; Kong L
    Acta Biomater; 2018 Sep; 77():268-281. PubMed ID: 30006311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate.
    Hu M; Huang P; Wang Y; Su Y; Zhou L; Zhu X; Yan D
    Bioconjug Chem; 2015 Dec; 26(12):2497-506. PubMed ID: 26497258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An implantable depot capable of in situ generation of micelles to achieve controlled and targeted tumor chemotherapy.
    Luo X; Chen M; Chen Z; Xie S; He N; Wang T; Li X
    Acta Biomater; 2018 Feb; 67():122-133. PubMed ID: 29242159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.
    Gleixner KV; Mayerhofer M; Vales A; Gruze A; Hörmann G; Cerny-Reiterer S; Lackner E; Hadzijusufovic E; Herrmann H; Iyer AK; Krauth MT; Pickl WF; Marian B; Panzer-Grümayer R; Sillaber C; Maeda H; Zielinski C; Valent P
    Curr Cancer Drug Targets; 2009 Aug; 9(5):675-89. PubMed ID: 19508170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.